Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (2617)	1/19/2001 11:55:53 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Torben, No, I don't believe this has any relevance to patents like those sought by INCY. The issues with INCY patents center around standards for granting bare-bones gene patents with utility, novelty and scope amongst others issues in question. But always remember that in any event INCY is basing its fortunes mainly on contractual agreements, not patents. The AMGN patent was a standard biotech patent that TKTX was attempting an end-run around. Somehow people got the mistaken impresssion that if TKTX won, then every biotech patent was in issue. In fact, as I understand it, this was very much a fact-based case, centering on the specifics of AMGN's patents and claims. Peter